Navigation Links
Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results
Date:2/27/2008

nual Health Care Conference, March 17-20, 2008, Boston,

Massachusetts

-- Lehman Brothers Eleventh Annual Global Healthcare Conference,

March 18-20, 2008, Miami, Florida

-- 8th Annual Fortis Biotechnology Conference, April 3, 2008, London,

England

-- 2008 Morgan Stanley Global Healthcare Unplugged Conference,

April 30-May 2, 2008, Key Biscayne, Florida

-- Deutsche Bank 33rd Annual Health Care Conference, May 5-7, 2008,

Boston, Massachusetts

-- Bank of America 2008 Health Care Conference, May 13-15, 2008, Las

Vegas, Nevada

-- Rodman & Renshaw 5th Annual Global Healthcare Conference, May 19-20,

2008, Monte Carlo, Monaco

About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is being investigated in a Phase 3 clinical trial program for the treatment of obesity. Arena's broad pipeline of novel compounds targeting G protein-coupled receptors, an important class of validated drug targets, includes compounds being evaluated independently and with its partners, Merck & Co., Inc. and Ortho-McNeil Pharmaceutical, Inc.

Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the company. "APD" is an abbreviation for Arena Pharmaceuticals Development.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about the significance of 2007 events and activities; expected 2008 events and activities; upcoming milestones, including the timing of the month-12 ESMB review of lorcaserin, and the importance of such milestones; the protocol, des
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Arena Pharmaceuticals to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
3. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
4. Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index
5. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Arena Pharmaceuticals to Report Third Quarter 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, October 17, 2007
7. Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results
8. Arena Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Arena Pharmaceuticals Appoints Phillip M. Schneider and Randall E. Woods to Board of Directors
10. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
11. Arena Pharmaceuticals Enters Into Strategic Agreements for the Manufacture of Pharmaceutical Material, Including Lorcaserin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... , June 18, 2013 RegeneCure ... the company,s  proprietary AMCA Guided Bone Regeneration (GBR) Dental Membrane ... A common problem encountered when patients have a ... sufficient bone volume to house the implant. Consequently there is ... substitute until the natural bone regenerates. The bone substitute material, ...
(Date:6/18/2013)... 2013 The "Bioinformatics Market By Sector (Molecular ... Tools & Data Analysis Services) & Application (Genomics, Proteomics & ... Market Drivers, Restraints, and Opportunities in North America ... and Rest of World. Browse ... 22 Figures 364 Pages and ...
(Date:6/18/2013)... 2013 Research and ... addition of the "Injectable Drug Delivery ... Devices [Disposables & Reusable, Fillable & Prefilled, ... Therapeutics [Diabetes & Oncology] - Global Forecasts ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , ...
(Date:6/18/2013)... Inflamax Research Inc., a full service ... I-IV clinical trials, announced today that they will ... Technologies (NAET), a specialty air conditioning & environmental ... of mobile Environmental Exposure Chambers (EECs) used in ... , Inflamax Research has proprietary Next Generation ...
Breaking Biology Technology:RegeneCure Starts Clinical Study Using Polymeric Bone Stimulating Membrane for Dental Implants 2RegeneCure Starts Clinical Study Using Polymeric Bone Stimulating Membrane for Dental Implants 3Bioinformatics Market Worth $7.5 Billion by 2017 2Bioinformatics Market Worth $7.5 Billion by 2017 3Injectable Drug Delivery Market by Formulations, Devices & Therapeutics - Global Forecasts to 2017 2Injectable Drug Delivery Market by Formulations, Devices & Therapeutics - Global Forecasts to 2017 3Inflamax Research Inc. Enters Strategic Partnership with Northern Air Environmental Technologies Inc. 2Inflamax Research Inc. Enters Strategic Partnership with Northern Air Environmental Technologies Inc. 3
... Perceptive Informatics , a leading eClinical solutions ... PRXL ), today unveiled the new release ... provides richer functionality to further streamline the clinical trial ... clinical trial sponsors to more efficiently manage the clinical ...
... films ever made on a device the size of an ... could make it possible to build radically smaller storage devices ... devices. There,s just one obstacle on the way. Nano-sized magnets ... hairs above absolute zero. Now a chemistry student at the ...
... March 28, 2011 DRIVE4COPD, the nation,s single largest ... named PRWeek,s Healthcare Campaign of the Year ... the most prestigious honors in the public relations industry, ... and education teams.  Boehringer Ingelheim Pharmaceuticals, Inc. is the ...
Cached Biology Technology:Perceptive Informatics Introduces DataLabs® 5.0 EDC Solution, Unlocking New Clinical Trial Process Efficiencies 2Perceptive Informatics Introduces DataLabs® 5.0 EDC Solution, Unlocking New Clinical Trial Process Efficiencies 3Perceptive Informatics Introduces DataLabs® 5.0 EDC Solution, Unlocking New Clinical Trial Process Efficiencies 4Perceptive Informatics Introduces DataLabs® 5.0 EDC Solution, Unlocking New Clinical Trial Process Efficiencies 5Heavy metals open path to high temperature nanomagnets 2DRIVE4COPD Wins PRWeek Healthcare Campaign of the Year 2011 2DRIVE4COPD Wins PRWeek Healthcare Campaign of the Year 2011 3DRIVE4COPD Wins PRWeek Healthcare Campaign of the Year 2011 4
(Date:6/17/2013)... -- As mobile devices, smartphones and tablets become ... exponentially, and biometric authentication offers that security, according ... Insider ( www.heavyreading.com/mobile-networks ), a subscription research ... ). Biometrics Offer Promise for More ... on smartphones, analyzing the most lucrative verticals for ...
(Date:6/17/2013)... Entrepreneurship will be the topics under discussion during ... For the third consecutive year, this will be ... of experiences among members of Academy, Business, Educators, ... Confirmed speakers: Elisa Martn Garijo (IBM South Europe), ... and Mary O,Donovan (Hovione), among others. E3 Forum ...
(Date:6/16/2013)... 16, 2013)Male mice who were fed a high-fat diet ... who also had higher levels of body fat, a ... observed primarily in male offspring, despite their consumption of ... meeting of The Endocrine Society in San Francisco, Calif. ... affect metabolism and behavior of offspring dependent on the ...
Breaking Biology News(10 mins):Biometric Authentication Provides Better Mobile Device Security, Heavy Reading Finds 2Biometric Authentication Provides Better Mobile Device Security, Heavy Reading Finds 3'E3 Forum -- Education, Employment & Entrepreneurship on a Global context' 2Obese male mice father offspring with higher levels of body fat 2
... trials ever, researchers have found that an experimental vaccine ... of shingles--a painful nerve and skin infection--and dramatically reduced ... the disease. The findings appear in the June 2 ... The Shingles Prevention Study, conducted over 5 ½-years, was ...
... for pandemic influenza, a new study reports for the first ... spread from poultry to humans. The research appears in ... now available online. , Crossing the species barrier is an ... pandemic potential. Previous studies have focused on the ability of ...
... Two peas in a pod may not be so friendly when ... plant, once separated may treat the former conjoined twin as an ... looking at how plants determine who is a competitor when competing ... researcher in plant ecology. "There is no reason for roots to ...
Cached Biology News:Experimental shingles vaccine proves effective in nationwide study 2Experimental shingles vaccine proves effective in nationwide study 3Experimental shingles vaccine proves effective in nationwide study 4Less virulent strains of avian influenza can infect humans 2Plants discriminate between self and non self 2
Request Info...
... Chemicon's 3243 provides all the materials necessary ... use in CMV antigen studies analysis. Kit ... - (Catalog No. 5122) One bottle containing 220 ... Fixation Solution (5X) - (Catalog No. 5113) ...
... For use with suspension (non-adherent) ... uses vacuum filtration or centrifugation ... media. Compatible with 96-well ... in larger package sizes and ...
... The Zero Background/Kan Cloning ... with kanamycin resistance for selection ... vector utilizes positive selection to ... contains all of the reagents ...
Biology Products: